TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04712032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG-guided bowel perfusion assessment
Description: ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
Study: NCT03241810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is an estrogen receptor antagonist with no agonist effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant is an estrogen receptor antagonist with no agonist effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03887611

Intervention type: DEVICE
Intervention: Ultrasound diagnosis
Description: Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
Study: NCT01513005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy
Description: the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance
Study: NCT00726505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, up to 29 days:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, up to 29 days:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, up to 29 days:
Study: NCT02356874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
Study: NCT06413888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
Study: NCT02745756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Progenitor Cell Transplant
Description: Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH and Tumor Lysate Pulsed DC Vaccine
Description: Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
Study: NCT02644382

Intervention type: OTHER
Intervention: qualitative data collection
Description: qualitative data collection

Intervention type: OTHER
Intervention: qualitative data collection
Description: qualitative data collection

Intervention type: OTHER
Intervention: qualitative data collection
Description: qualitative data collection
Study: NCT00871715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose-Equivalent Usual & Customary Care - DEUCC
Description: Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual and Customary Care - UCC
Description: Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
Study: NCT02644382

Intervention type: OTHER
Intervention: survey
Description: survey pre and post-surgical consult

Intervention type: OTHER
Intervention: survey
Description: survey pre and post-surgical consult

Intervention type: OTHER
Intervention: decision aid
Description: web-based decision aid post-surgical consult
Study: NCT01154751

Intervention type: DEVICE
Group type: OTHER
Intervention: SUPERA Interwoven self-expanding nitinol stent
Description: Insertion of stent at stenotic area
Study: NCT01708668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus
Study: NCT04343118

Intervention type: PROCEDURE
Intervention: Hardware Removal
Description: elective removal of plate osteosynthesis at the clavicle
Study: NCT03385330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOWER oxygen saturation target group
Description: We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIGHER oxygen saturation target group
Description: We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
Study: NCT02622646

Intervention type: DRUG
Intervention: Recombinant VIII factor
Description: Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).

Intervention type: DRUG
Intervention: Recombinant VIII factor
Description: Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Study: NCT03005808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Surgery for appendicitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Surgery for appendicitis
Study: NCT01462890

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 175 mg/m², iv on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m², iv on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 5, iv on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, iv on day 1 every 3 weeks for 6 cycles

Intervention type: OTHER
Group type: OTHER
Intervention: specialized pathology review (Germany only)
Description: before randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specialized pathology review (Germany only)
Description: before randomization
Study: NCT01024192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOLPIDEM SL800750
Description: Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)
Study: NCT00086411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal system
Description: starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system
Description: starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management
Description: Brief manual based therapy; four 15 minute session over 10 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medication Management
Description: Brief manual based therapy; four 15 minute session over 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mayo Counseling
Description: Manual based therapy; Weekly 30 minute sessions for 10 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mayo Counseling
Description: Manual based therapy; Weekly 30 minute sessions for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: placebo patch containing no nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: placebo patch containing no nicotine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bupropion
Description: placebo pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo bupropion
Description: placebo pills
Study: NCT04465812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring and personalized feedback on smartphone app
Description: 1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app
Study: NCT00718770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
Study: NCT02162966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Colistin
Description: High Dose Colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Colistin
Description: Standard Dose Colistin
Study: NCT01624090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: 30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
Study: NCT01954563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
Study: NCT01895309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel (etanercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB4 (proposed biosimilar to etanercept)
Study: NCT03173768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ID specialist approval
Description: Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
Study: NCT02189681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional landmark guided midline spinal anaesthesia
Description: Spinal anaesthesia was administered based on conventional landmark based midline approach.
Study: NCT04038437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 will be administered on Days 1 and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be adminstered on Days 2 to 21 of each cycle
Study: NCT04407273

Intervention type: DRUG
Intervention: observational
Description: observational study

Intervention type: DRUG
Intervention: observational
Description: observational study
Study: NCT04615351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Medication
Study: NCT00228917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine
Study: NCT02189681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-procedure ultrasound guided L5S1 paramedian spinal
Description: In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anaesthesia
Description: Spinal anaesthesia is administered with appropriate spinal needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: Spinal anaesthesia is administered with appropriate spinal needle
Study: NCT03134690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed start
Description: In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional
Description: In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
Study: NCT03504748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo deep rTMS
Study: NCT05277428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTB1
Description: 2 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsule/day
Study: NCT01457846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Infusion administered once a week, 3 weeks on and 1 week off
Study: NCT02526225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection simulation
Description: 5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
Study: NCT04365192

Intervention type: DEVICE
Intervention: I-gel
Description: The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary.

Intervention type: DEVICE
Intervention: Self-pressurized air-Q
Description: The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
Study: NCT03093701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399 (ProDex)
Description: 2-vial system: TLC399-DSP and TLC399-Lipid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399 (ProDex)
Description: 2-vial system: TLC399-DSP and TLC399-Lipid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399 (ProDex)
Description: 2-vial system: TLC399-DSP and TLC399-Lipid
Study: NCT04196010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study: NCT00014560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bispecific antibody 4G7xH22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT00968929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Streptokinase
Description: Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
Study: NCT02698176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered as an oral capsule in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered as an oral capsule in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered as an oral capsule in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered as an oral capsule in a fasted state
Study: NCT02183220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (ASA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizol placebo